Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 27;12:10263–10273. doi: 10.2147/OTT.S223406

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Immunological characteristics are different in Siglec-5, −7, −9, and −16. (A) Expression of Siglec-5, −7, −9, and −16 in glioma cells of each WHO grade. The expression level is represented by the shade of red. Gray indicates no expression. (B) Expression of Siglec-16 and immune checkpoints in glioma cells of each WHO grade. The expression level is represented by the shade of red. Gray indicates no expression. (C) Spatial mapping analysis of each WHO grade glioma. Red indicates that Siglec was expressed in the cell. Cells without Siglec expression are colored blue. (D) The distribution proportion of Siglec members in each cell type. (E) Number of immune cells with Siglec members expressed.